Aripiprazole cardiosafety: Is it overestimated?
Main Author: | Ahmed Naguy |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
Series: | Journal of Family Medicine and Primary Care |
Online Access: | http://www.jfmpc.com/article.asp?issn=2249-4863;year=2016;volume=5;issue=3;spage=736;epage=737;aulast=Naguy |
Similar Items
-
A comment on “add-on aripiprazole for atypical antipsychotic-induced, clinically significant hyperprolactinemia”
by: Ahmed Naguy
Published: (2018-01-01) -
MODERN POSSIBILITIES OF THERAPY OF TYPE 2 DIABETES MELLITUS PATIENTS. EFFECTIVENESS AND CARDIOSAFETY OF ALOGLIPTIN FROM THE POINT OF VIEW OF EVIDENCE-BASED MEDICINE
by: A. S. Ametov, et al.
Published: (2017-07-01) -
Aripiprazol e síndrome de Tourette Aripiprazole and Tourette syndrome
by: Ana Hounie, et al.
Published: (2004-09-01) -
The clinical utility of serum level of Aripiprazole and Dehydro-aripiprazole in schizophrenia
by: Hui-Hsin Chuang, et al.
Published: (2016) -
Train-of-Four monitoring: overestimation
by: Jeong Uk Han
Published: (2011-05-01)